New Complete Response in the Concurrent BTKi azer-cel Cohort
Open PDF
| Stock | Imugene Ltd (IMU.ASX) |
|---|---|
| Release Time | 1 Jul 2026, 10 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Imugene Reports Additional Complete Response in BTKi Cohort
Key Points
- Additional complete response in BTKi cohort
- First Mantle Cell Lymphoma patient treated
- Patient had previously failed BTKi therapy
Full Summary
Imugene Limited (ASX: IMU) announced an additional complete response in the concurrent BTKi cohort of its ongoing Phase 1b study of azer-cel (azercabtagene zapreleucel). This Mantle Cell Lymphoma (MCL) patient, the first MCL patient treated in the azer-cel Phase 1b study, had previously failed BTKi therapy and achieved a complete response at the Day 28 assessment. MCL is an aggressive B-cell non-Hodgkin lymphoma that typically presents at an advanced stage and remains incurable with standard therapies. BTK inhibitors have become an established treatment across relapsed or refractory MCL, but a significant proportion of patients develop resistance over time, leaving them with limited remaining options.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In